z-logo
Premium
Quinolizidinyl‐benzimidazoles as Platelet‐Antiaggregating Agents
Author(s) -
Vazzana Iana,
Terranova Emanuela,
Tasso Bruno,
Tonelli Michele,
Piana Antonietta,
Gastaldi Stefanella,
Sparatore Fabio
Publication year - 2008
Publication title -
chemistry and biodiversity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 70
eISSN - 1612-1880
pISSN - 1612-1872
DOI - 10.1002/cbdv.200890068
Subject(s) - chemistry , epimer , agonist , benzimidazole , platelet aggregation , selectivity , platelet , stereochemistry , receptor , biochemistry , medicine , organic chemistry , catalysis
Two series of (±)‐2‐phenyl‐1‐(quinolizidin‐1 α ‐yl)benzimidazoles, 12A – 26A , and (±)‐2‐phenyl‐1‐(quinolizidin‐1 β ‐yl)benzimidazoles, 12B – 26B , were prepared and tested for the inhibition of human platelets aggregation induced by ADP, collagen, and adrenaline. All epimers A , i.e. , 12A – 26A , were devoid of any activity against the three agonists, while the epimers B , i.e. , 12B – 26B , exhibited different degrees of activity, though practically confined against the ADP‐induced aggregation. The best compounds were 19B, 24B , and 26B , which inhibited for 69–67% at 260 μ M and for 40–29% at 65 μ M concentration the ADP (2 μ M )‐induced aggregation. The observed agonist and spatial structure selectivity warrant further investigations of this kind of benzimidazole derivatives.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here